Hansa Biopharma AB (OSTO:HNSA) Total Equity: kr-275.3 Mil (As of Mar. 2026)


OSTO:HNSA Hansa Biopharma AB OSTO:HNSA
50 GF Score
Price kr34.88
GF Value kr24.51
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Hansa Biopharma AB Total Equity?

Hansa Biopharma AB OSTO:HNSA -0.34% 50 Total Equity is kr-275.3 Mil as of Mar. 2026. GuruFocus rates OSTO:HNSA with a GF Score™ of 50/100 and a GF Value™ of kr24.51 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Hansa Biopharma AB's total equity for the quarter that ended in Mar. 2026 was kr-275.3 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Hansa Biopharma AB Total Equity Historical Data

* Premium members only.

The historical data trend for Hansa Biopharma AB's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hansa Biopharma AB Total Equity Chart

Hansa Biopharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 757.57 602.91 -167.88 -589.83 -88.99

Hansa Biopharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -623.74 -441.06 -560.74 -88.99 -275.27
OSTO:HNSA
50GF Score
Hansa Biopharma AB OSTO:HNSA
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hansa Biopharma AB Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Hansa Biopharma AB's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1166.767-1255.759
=-89.0

Hansa Biopharma AB's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=1162.191-1437.457
=-275.3

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of kr-275.3 Mil mean?
Hansa Biopharma AB (OSTO:HNSA) has a Total Equity of kr-275.3 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Hansa Biopharma AB and its competitors.
Is Hansa Biopharma AB's Total Equity too high?
Hansa Biopharma AB's current Total Equity is kr-275.3 Mil. Overall, Hansa Biopharma AB has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hansa Biopharma AB's Total Equity compare to VRTX and REGN?
Hansa Biopharma AB's Total Equity of kr-275.3 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Hansa Biopharma AB and its competitors. Hansa Biopharma AB's current Total Equity is kr-275.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansa Biopharma AB stock overvalued right now?
Based on GuruFocus' analysis, Hansa Biopharma AB (OSTO:HNSA) is currently considered Significantly Overvalued. The stock's GF Value™ is kr24.51, compared to a current price of kr34.88 — trading 42.3% above its estimated fair value. The current Total Equity is kr-275.3 Mil. Hansa Biopharma AB's overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Hansa Biopharma AB (OSTO:HNSA), the current Total Equity is kr-275.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hansa Biopharma AB (OSTO:HNSA) Overvalued in 2026?

Based on GuruFocus' analysis, Hansa Biopharma AB stock appears to be overvalued. The current stock price of kr34.88 is trading 42.3% above its estimated GF Value™ of kr24.51. GuruFocus considers Hansa Biopharma AB to be Significantly Overvalued.

Key valuation signals for OSTO:HNSA:

  • Total Equity: kr-275.3 Mil
  • GF Value™: kr24.51 vs. price of kr34.88 (42.3% above fair value)
  • GF Score™: 50/100 with 6 warning signs

No single metric tells the full story. See the OSTO:HNSA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hansa Biopharma AB Business Description

Address Scheelevagen 22, Lund, SWE, 223 63
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies for patients with rare immunological conditions. It has developed a proprietary, first-in-class antibody-cleaving enzyme technology platform designed to eliminate pathogenic IgG antibodies. This differentiated platform supports a broad pipeline with potential applications across Transplantation, Autoimmune diseases, and Gene Therapy-areas characterized by unmet medical need. Hansa's first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate all four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in both the intravascular and extravascular compartments following a single intravenous administration.
50GF Score

Get the complete analysis for OSTO:HNSA

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr34.88
Price
kr24.51
GF Value